You are here

P&T® Journal contents for March 2003

Features

The author reviews the reasons for FDA labeling changes for estrogens and estrogen–progesterone combinations as hormonal therapy; sertraline for depression; and palivizumab as prophylactic therapy for respiratory infections.
Marvin M. Goldenberg, PhD, RPh, MS
The authors present the results of a survey sent to the directors of MCOs to ascertain their views on chronic pain in their patients.
Chureen Carter, PharmD, Neil I. Goldfarb, Christine W. Hartmann, MSS, Adam R. Roumm, Susan M. Vallow, MBA, MA, and Michael Durkin, MS
The first of the new selective cholesterol absorption inhibitors, ezetimibe has been approved for several indications.
Beata M. Domagala, PharmD, Michelle Leady, PharmD, and Daniel S. Streetman, PharmD
Cover Story
Now is the time to order vaccine for the fall flu season. The authors discuss the ways in which many diseases in older adults could be prevented with more effective immunization strategies.
S. Jay Weaver, PharmD, and Paul L. Doering, MS Pharm

Departments

Editorial
David B. Nash, MD, MBA
Spotlight
P&T is now accessible on the World Wide Web. But wait, there’s more!
Sonja Sherritze
Medication Errors
Matthew Grissinger discusses some key words that should be considered “red flags.”
Matthew Grissinger
Drug News
The latest information about approvals, indication changes, industry updates, and news from the FDA.
Prescription Washington
Stephen Barlas ponders the tragic loss of life caused by a medical error.
Stephen Barlas
Drug Forecast
Dr. Liang-Kim reviews the role of interferon beta-1a in multiple sclerosis.
Kathleen S. Liang-Kim, RPh